PARIS, 1 July 2021 – Bryan, Garnier & Co, a leading pan-European investment bank focusing on growth companies, is delighted to announce that Jérôme Guyot has been appointed as Managing Director, ECM at the firm.

 Based in Paris, Jérôme will help further drive Bryan, Garnier & Co’s ECM franchise and help the firm achieve its ambition to become the leader in ECM for growth companies.

Jérôme, 45, has a 15-year career in the investment banking industry. Before joining Bryan, Garnier & Co, he worked at a variety of companies including Gilbert Dupont – Groupe Société Générale, where he was Head of ECM and then Co-Head of Corporate Finance, and Groupe Crédit du Nord as Director, ECM.

Over his career, Jérôme has executed more than 70 ECM transactions across a range of industries, including tech, healthcare, and consumer, which are core sectors for Bryan, Garnier & Co. He has completed advisory and capital markets transactions for clients such as Advicenne, Alchimie, Ateme, Ekinops, Fermentalg, Gensight Biologics, Inventiva, Median Technologies, Nacon, Nanobiotix and Sidetrade.

Christophe Alleman, Co-Head Equity Capital Markets states: “We are delighted to welcome Jérôme to Bryan, Garnier & Co as Managing Director in our Equity Capital Markets franchise. Jérôme brings a long and established track record of ECM success in the French small and mid-cap market, which represents the largest pool of publicly listed small and mid-cap companies in continental Europe.”

 Jérôme Guyot comments: “I am more than happy to join Bryan, Garnier & Co’s highly committed team to help expand our ECM franchise. I have been very impressed by the ability of the firm to bring in strategic cornerstone investors in the context of IPOs and follow-on offerings. This is a perfect illustration of the firm’s value proposition to support growth companies and disruptive players at all stages of their development”.

With more than 60 private and public capital-raising and M&A transactions closed in 2020, Bryan, Garnier & Co benefits from longstanding leadership in the healthcare, technology, business services and environmental sectors in Europe. Over the past 36 months, Bryan, Garnier & Co has led more than 40 ECM transactions across nine countries, raising over EUR 2.5bn. Recent successes include the IPOs and/or follow-ons for HDF Energy (Euronext Paris), Mister SPEX (Deutsche Boerse), Carbios (Euronext Paris), Azelio (NASDAQ Stockholm), McPhy Energy (Euronext Paris), Linas Matkase (NASDAQ Stockholm), Heidelberg Pharma (Deutsche Börse), Swedish Stirling (NASDAQ Stockholm), Basilea (SIX) GenSight (Euronext Paris), and Valneva (NASDAQ / Euronext Paris).

Additional recent transactions include the acquisition of DL Software by TA Associates, the sale of smartTrade to leading software private equity investor Hg Capital, the take-private of ITSM player Easyvista by Eurazeo, capital for circular economy player asgoodasnew, the sale of Specim to Konica Minolta and the sale of BlueBee to Illumina. Over the years, Bryan, Garnier & Co has distinguished itself by backing some of the most disruptive companies in the domain of alternative proteins (Prolupin), green hydrogen (McPhy Energy), cannabis (Canopy Growth), 3D printing (Materialise), blockchain and cryptocurrencies (Bitfury Group), and mRNA biotech (Moderna and BioNTech).

About Bryan, Garnier & Co

Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in the UK, the AMF in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo, Reykjavik and New York.

(www.bryangarnier.com)